Technology Bundle ID
TAB-2638

Isolated Lyssavirus Nucleic Acid and Protein Sequences

Linked ID
E-179-2013-0
Lead Inventors
Ivan Kuzmin (CDC)
Co-Inventors
Charles Rupprecht (CDC)
Wanda Markotter (University of Pretoria)
Development Status
  • Early-stage
  • In vitro data available
Therapeutic Areas
Infectious Disease
ICs
CDC
A novel strain in the rabies family of viruses, the Shimoni bat virus (SHIBV), has been discovered. Phylogenic and antigenic patterns identify SHIBV as a new species of Lyssavirus. Phylogenic reconstructions of SHIBV and monoclonal antibody typing were used to demonstrate a distinct genetic antigenic pattern. This unique genetic information may be used to create antigens or vaccines against SHIBV and provides opportunity for the development of new diagnostics, therapeutics, and prophylactic therapies for viral infection.
Commercial Applications
  • Vaccines, therapies or diagnostics for Shimoni bat virus
  • Rabies epidemiology and surveillance
  • Lyssavirus/rabies research tool
Competitive Advantages
  • Protects against phylogroup II lyssaviruses, unlike current commercially available rabies vaccines
  • Isolated biomaterials provide novel lyssavirus research tools

Request More Info